Paper39405607
Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance.
Qin R and 11 others. Transl Oncol, 2024. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance. Papers, record 39405607. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39405607
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References127
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22228080 | Metabolic symbiosis in cancer: refocusing the Warburg lens. | Mol Carcinog | 2013 | https://conductscience.org/library/papers/22228080 | PubMed |
| 2 | 33244454 | Thrombospondin 2/Toll-Like Receptor 4 Axis Contributes to HIF-1α-Derived Glycolysis in Colorectal Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/33244454 | PubMed |
| 3 | 33546704 | The cancer metabolic reprogramming and immune response. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33546704 | PubMed |
| 4 | 36232922 | Molecular Pathogenesis of Colorectal Cancer: Impact of Oncogenic Targets Regulated by Tumor Suppressive miR-139-3p. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36232922 | PubMed |
| 5 | 37597817 | The interaction between apigenin and PKM2 restrains progression of colorectal cancer. | J Nutr Biochem | 2023 | https://conductscience.org/library/papers/37597817 | PubMed |
| 6 | 36200045 | Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/36200045 | PubMed |
| 7 | 30926638 | RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer. | Mol Cancer Ther | 2019 | https://conductscience.org/library/papers/30926638 | PubMed |
| 8 | 35288533 | An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35288533 | PubMed |
| 9 | 35441953 | Long Non-coding RNA LOXL1-AS1 Facilitates Colorectal Cancer Progression via Regulating miR-1224-5p/miR-761/HK2 Axis. | Biochem Genet | 2022 | https://conductscience.org/library/papers/35441953 | PubMed |
| 10 | 31375671 | LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. | Nat Commun | 2019 | https://conductscience.org/library/papers/31375671 | PubMed |
| 11 | 31781676 | PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling. | J Immunol Res | 2019 | https://conductscience.org/library/papers/31781676 | PubMed |
| 12 | 28761044 | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells. | Sci Rep | 2017 | https://conductscience.org/library/papers/28761044 | PubMed |
| 13 | 27922662 | Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells. | Int J Oncol | 2017 | https://conductscience.org/library/papers/27922662 | PubMed |
| 14 | 36695827 | Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/36695827 | PubMed |
| 15 | 31803611 | The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. | Front Oncol | 2019 | https://conductscience.org/library/papers/31803611 | PubMed |
| 16 | 38414789 | ENO1 deletion potentiates ferroptosis and decreases glycolysis in colorectal cancer cells via AKT/STAT3 signaling. | Exp Ther Med | 2024 | https://conductscience.org/library/papers/38414789 | PubMed |
| 17 | 38715141 | CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration. | Biol Direct | 2024 | https://conductscience.org/library/papers/38715141 | PubMed |
| 18 | 30936746 | Oncogenic role of ABHD5 in endometrial cancer. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/30936746 | PubMed |
| 19 | 36929658 | Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells. | Biofactors | 2023 | https://conductscience.org/library/papers/36929658 | PubMed |
| 20 | 32110048 | HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells. | Onco Targets Ther | 2020 | https://conductscience.org/library/papers/32110048 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979438 | Aspirin induces glycolytic reprogramming via lysine salicylation of ALDOA. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42979438 | PubMed |
| 42897352 | NUAK isoforms promote glucose and glutamine metabolic reprogramming driven colon cancer progression and migration through regulation of AMPK/mTOR signaling. | J Mol Med (Berl) | 2026 | https://conductscience.org/library/papers/42897352 | PubMed |
| 42758364 | Mitochondrial metabolite transporters at the crossroads of metabolic reprogramming, epigenetic regulation and therapeutic vulnerabilities in colorectal cancer. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42758364 | PubMed |
| 42597529 | GSG2 promotes aerobic glycolysis and colorectal cancer progression via the MDM2-p53 axis. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42597529 | PubMed |
| 42591618 | High SRD5A2 expression is associated with poor prognosis and promotes tumor cell progression in colorectal cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591618 | PubMed |
| 42465030 | RPS2 and EEF1B2 are associated with glycolysis-related malignant phenotypes in COAD. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42465030 | PubMed |
| 42418117 | METTL3-YTHDF1-driven m6A enhancement of MYC signaling orchestrates DNA repair and metabolic reprogramming to promote chemoresistance in colorectal cancer. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42418117 | PubMed |
| 42400616 | Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42400616 | PubMed |
| 42346101 | Determinants of Colorectal Cancer: An Integrative Immunometabolic Framework Linking Biomarkers, Therapy, and the Diet-Microbiota Axis. | Cells | 2026 | https://conductscience.org/library/papers/42346101 | PubMed |
| 42106773 | Integrative single-cell and spatial multi-Omics analyses identify NETs-driven colon cancer subtypes with distinct metabolic features and prognostic implications. | J Transl Med | 2026 | https://conductscience.org/library/papers/42106773 | PubMed |
| 42076017 | Diagnostic Potential of Exosomes in Colorectal Cancer: Current Advances and Future Perspectives. | Molecules | 2026 | https://conductscience.org/library/papers/42076017 | PubMed |
| 41923267 | FBXO39 promotes LDHA-mediated aerobic glycolysis and colorectal cancer progression by p53 degradation. | J Transl Med | 2026 | https://conductscience.org/library/papers/41923267 | PubMed |
| 41803973 | Fusobacterium nucleatum promotes tumor progression driven by histone lactylation through increasing GLUT1 expression in colorectal cancer. | J Transl Med | 2026 | https://conductscience.org/library/papers/41803973 | PubMed |
| 41771836 | Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41771836 | PubMed |
| 41688960 | A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma. | BMC Biotechnol | 2026 | https://conductscience.org/library/papers/41688960 | PubMed |
| 41586238 | Impact of metabolic risk factors on colorectal cancer burden in China: a comprehensive analysis of trends from 1990 to 2021. | Front Nutr | 2025 | https://conductscience.org/library/papers/41586238 | PubMed |
| 41465299 | The Role of Gut Microbiota in Colorectal Cancer Pathogenesis: A Comprehensive Literature Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465299 | PubMed |
| 41415548 | Microbiota-host metabolism reprogramming in colorectal cancer: from pathogenesis to precision therapies. | Front Oncol | 2025 | https://conductscience.org/library/papers/41415548 | PubMed |
| 41387212 | Exercise serum promotes DNA damage repair and remodels gene expression in colon cancer cells. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41387212 | PubMed |
| 41327072 | The metabolic crossroads: glycolysis in cancer and neurodegeneration. | BMC Neurol | 2025 | https://conductscience.org/library/papers/41327072 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39405607
GET https://conductscience.org/api/papers/v1/39405607/references?page=2